We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Full Spectrum Endoscopy Reduces “Miss Rate” of Adenomas

By HospiMedica International staff writers
Posted on 30 May 2013
A wide-field endoscopy system significantly improves the accuracy of adenoma detection during colonoscopy procedures. More...


The EndoChoice (Atlanta, GA, USA) Fuse system is a proprietary arrangement of three small cameras at the tip of a flexible gastrointestinal (GI) endoscope. By using three cameras, the system allows doctors to see nearly twice as much surface area as they can with traditional endoscopes, since the wider angles allow examination of folds that occur naturally in the colon and stomach anatomy, problem areas that can easily go undetected when using traditional one-camera endoscopes.

In a study conducted by researchers at the Israel Institute of Technology (Technion; Haifa, Israel) and other institutions, researchers compared traditional endoscopes to the Fuse system. The endoscope used in the first examination was selected randomly, and the patient immediately underwent a second colonoscopy performed by the same doctor with the Fuse endoscope. The 185 patient trial showed traditional colonoscopes missed 42% of adenomas, while the Fuse system missed just 8%, reflecting an incremental find rate of 71%. The study was presented at Digestive Disease Week (DDW), held during May 2013 in Orlando (FL, USA).

“Traditional endoscopes provide up to 170° of forward vision. The advantage of Fuse is that it allows endoscopists to examine twice the anatomy with a wide 330° view,” said study presenter Ian Gralnek, MD, of the Technion. “Our findings are compelling and support the data from previous studies showing the limitations of traditional endoscopes. EndoChoice's innovative Fuse technology dramatically improves the effectiveness of this life-saving procedure.”

“Since we announced the expansion of our company in January, our teams in Israel, Germany, and the United States have been working diligently to develop and launch the revolutionary Fuse endoscopy system,” said Mark Gilreath, Founder and CEO of EndoChoice, commenting on the Fuse system receiving the approval of the US Food and Drug Administration (FDA), announced during DDW 2013.

Related Links:

EndoChoice
Israel Institute of Technology



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Vessel Sealing Instrument
ERGOseal
New
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.